ERBB2 and neoplasm: In summary, our study reveals that (1) A subset of breast cancer patients with a better prognosis a priori, such as estrogen-receptor positive with or without Her2 positivity, develop brain metastases if FN14 and/or GRP94 biomarkers are positive in their primary tumor.